Phase two trials of a Chinese coronavirus vaccine have shown the drug is safe and triggers an immune response. The researchers came to this conclusion after conducting experiments on adult volunteers. The details of the study can be read in the peer-reviewed medical journal The Lancet.
According to the data obtained, the vaccine has shown its safety for humans. 603 people took part in the vaccine trials. They also conducted trials in a small subset of people aged 55 and over. This data will be used in the third phase of the vaccine trial.
However, the authors note that none of the participants were exposed to the SARS-CoV-2 virus after vaccination, so they cannot say with complete certainty that this is the most effective protection against coronavirus.
The second phase of testing is very important for us: it showed that our vaccine is safe and immunogenic in a large part of the population. This is an important step in the early evaluation of this experimental vaccine. We will be moving on to the third phase of testing soon.
Feng-Cai Zhu, Center for Disease Control and Prevention, Jiangsu Province, China
Currently, about 250 vaccines are being developed in the world that can potentially be used against coronavirus. Among them there are messenger RNA vaccines, replicating or non-replicating viral vector vaccines, DNA-based vaccines, autologous dendritic cell vaccines, and others. At least 17 of them are in clinical trials.
Researchers from the UK also announced a successful second phase of testing. The drug was tested on a thousand volunteers – it turned out to be effective and safe. Earlier, the UK signed agreements to provide 90 million doses of two possible vaccines against COVID-19 from the alliance of Pfizer Inc (PFE.N) and BioNTech (22UAy.F), and the French group Valneva (VLS.PA). This was reported by the authorities on Monday.